Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results

Go back to Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results

Hims and Hers (HIMS) PT Lowered to $14 at Jefferies

May 7, 2024 4:03 PM EDT

Jefferies analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $14.00 (from $15.00) while maintaining a Hold rating.

The analyst comments "We are updating our model following 1Q results. The updated model reflects the company's impressive profitability ramp... More

Hims and Hers (HIMS) PT Raised to $16 at Deutsche Bank

May 7, 2024 5:24 AM EDT

Deutsche Bank analyst George Hill raised the price target on Hims and Hers (NYSE: HIMS) to $16.00 (from $14.00) while maintaining a Hold rating.

The analyst comments "Based on the strong momentum in Q1, management raised the 2024 revenue guidance by $30 million at the... More

Hims & Hers Health, Inc. (HIMS) Tops Q1 EPS by 4c, Offers Guidance

May 6, 2024 4:09 PM EDT

Hims & Hers Health, Inc. (NYSE: HIMS) reported Q1 EPS of $0.05, $0.04 better than the analyst estimate of $0.01. Revenue for the quarter came in at $278.2 million versus the consensus estimate of $270.44 million.

GUIDANCE:

Hims & Hers Health, Inc. sees Q2 2024 revenue of $292-292... More